I read a posting yesterday under "clinical trials" regarding the use of nanoparticles to fight ovarian cancer. The post contained a cross link to the MIT-Lankenau Institute research work. FYI, I published a post yesterday at Libby's H*O*P*E* entitled, "Novel Targeted Gene Therapies Use Diphtheria Toxin To Fight Ovarian Cancer; One Clinical Trial Underway."(http://healthinfoispower.wordpress.com/2009/08/10/novel-targeted-gene-thera pies-use-diphtheria-toxin-to-fight-ovarian-cancer-future-clinical-trials-an ticipated/). My post covers the work being done by the MIT-Lankenau research team, as well as similar work being conducted by an Israeli research team.
Although it appears that the MIT-Lankenau Institute research work is still in preclinical testing, the Israeli researchers are already testing their therapy in a Phase I/II clinical trial with locations in the U.S. & Israel. All of the details are set forth in the Libby's H*O*P*E* post.
The two U.S. trial locations are Univ. of Pennsylvania (Principal Investigator: George Coukos, M.D., Ph.D., Abramson Cancer Center, Philadelpha, PA, currently recruiting) & Massey Cancer Center in Richmond, VA (Principal Investigator: Cecelia H. Boardman, M.D., not yet recruiting)
The "targeted gene therapy" being tested in the clinical trial against advanced stage ovarian cancer is referred to as DTA-H19 or BC-819 (http://www.biocancell.com/bc-819). The trial is sponsored by BioCancell Therapeutics (http://www.biocancell.com/clinical-trials/ovariantrial).
There are also three trial locations in Israel. Simply refer to the Libby's H*O*P*E* post for more details.
For those who live near Philly or Richmond, this trial may be of interest in the event that you qualify. -- Paul, Founder, Libby's H*O*P*E*.





Add to the discussion